company score funding investors employees industries biz model city contact
Apollo Therapeutics

Portfolio of pharmaceutical research and discovery.

89
$33M · Series C Patient Square Capital, Rock Springs Capital, M&G Investments 1 to 10 Biotech, Pharma London, UK •••••••••••@apollotherapeutics.com
Causaly

Biomedical research discovery tool.

84
$60M · Series B Index Ventures, ICONIQ Growth, Pentech Ventures 51 to 100 Health Tech, AI, Biotech, Pharma B2B, SaaS London, UK •••••••••••@causaly.com
Baseimmune HIRING

AI vaccine algorithm developer.

84
$11M · Series A Hoxton Ventures, Merck Global Health Innovation Fund, Cherry Ventures 1 to 10 AI, Biotech B2B, SaaS London, UK •••••••••••@baseimmune.co.uk
Complement Therapeutics

Preclinical stage treatment for geographic atrophy.

84
$78M · Series A Forbion Capital Partners, Gimv 1 to 10 Biotech London, UK •••••••••••@complementtx.com
Beacon Therapeutics

Oophthalmic gene therapy company to treat blinding retinal illnesses.

84
$120M · Series A Syncona Partners LLP 1 to 10 Health Tech, Biotech London, UK •••••••••••@beacontx.com
IMU BiosciencesJUST ADDED

AI platform to map the human immune system.

75
$14M · Series A Molten Ventures, Life Extension Ventures 11 to 50 Health Tech, Biotech London, UK •••••••••••@imubiosciences.com
Tropic Biosciences

Tropic Biosciences is a pioneering leader in the development of novel high-performing commercial tropical crop varieties and traits.

75
$28M · Series B Future Planet Capital 11 to 50 Agritech, Biotech, Deep Tech, Manufacturing B2B London, UK •••••••••••@tropicbioscience.com
Mytos

Fully-automated cell manufacturing.

75
$19M · Series A Buckley Ventures, Wing Venture Capital, IQ Capital Partners 11 to 50 Biotech, Machine Learning B2B London, UK •••••••••••@mytos.bio
MIP DiscoveryJUST ADDED HIRING

Developer of non-biological affinity reagents to accelerate the production of cell and gene therapies.

75
$8M · Series A Mercia Asset Management 11 to 50 Health Tech, Biotech London, UK •••••••••••@mipdiscovery.com
Ori Biotech

Ori Biotech is a developer of a manufacturing platform used to help patients get access to lifesaving treatments.

75
$30M · Series A Kindred Capital, Octopus Ventures, Amadeus Capital 1 to 10 Health Tech, Biotech, Manufacturing B2B London, UK •••••••••••@oribiotech.com
FA Bio

Discovery and development platform of superior microbial bioproducts.

75
$6M · Series A Pymwymic, Clean Growth Fund 1 to 10 Biotech London, UK •••••••••••@fungialert.com
Quell Therapeutics

Quell Therapeutics is a cell therapy company

75
$45M · Series A AlbionVC, Point72 Ventures 101 to 250 Health Tech, Edtech, Biotech, Manufacturing B2B London, UK •••••••••••@quell-tx.com
Stanhope AIJUST ADDED HIRING

Neuroscience-driven AI platform.

68
$2M · Seed Rockmount Capital, Moonfire Ventures, UCL Technology Fund 11 to 50 AI, Biotech B2B, SaaS London, UK •••••••••••@stanhopeai.com
ReViral

ReViral is a biotechnology company that develops and offers antiviral therapies for patients.

68
$44M · Series C Novo A/S, Andera Partners 11 to 50 Health Tech, Biotech, Pharma B2B London, UK •••••••••••@reviral.co.uk
Charm Therapeutics

CHARM Therapeutics uses deep learning on 3D molecular configurations to develop molecule therapeutics to target pathogenic proteins.

68
$50M · Series A General Catalyst, Khosla Ventures 1 to 10 Health Tech, AI, Biotech, Data and Analytics B2B London, UK •••••••••••@charmtx.com
Laverock Therapeutics

Gene silencing platform for the creation of programmable, allogeneic cell therapies.

68
$16M · Seed Mercia Asset Management, Calculus Capital, UK Innovation & Science Seed Fund 1 to 10 Health Tech, Biotech London, UK •••••••••••@laverocktx.com
Lindus Health

Clinical trials platform.

68
$18M · Series A Valar Ventures, Creandum, Seedcamp 11 to 50 Health Tech, Biotech B2B, SaaS London, UK •••••••••••@lindushealth.com
LabGenius

LabGenius is a biopharmaceutical company developing protein therapeutics using a machine learning-driven evolution engine.

68
$25M Kindred Capital, Atomico 51 to 100 Health Tech, AI, Biotech, Deep Tech, Machine Learning, Robotics, Manufacturing B2B London, UK •••••••••••@labgeni.us
Achilles Therapeutics

Immunotherapies intended to offer next-generation, patient-specific therapies to treat cancer.

68
$17M · Seed AlbionVC, Boxer Capital, Syncona Partners LLP 101 to 250 Health Tech, Biotech B2B London, UK •••••••••••@achillestx.com
AstronauTx

Clinical-stage research for alzheimer’s disease.

67
$58M · Series A EQT Partners, UCL Technology Fund, Brandon Capital 1 to 10 Health Tech, Biotech Reading, UK •••••••••••@astronautx.bio
Beckley Psytech

Short-duration psychedelic medicines developer for neuropsychiatric conditions.

67
$40M · Series B ATAI Life Sciences, Leafy Tunnel 1 to 10 Biotech, Pharma B2C Oxford, UK •••••••••••@beckleypsytech.com
Umedeor

Platform to automate the clinical studies process.

64
$12M · Series A Playfair, AlbionVC, Delin Ventures 11 to 50 Health Tech, Biotech B2B London, UK •••••••••••@umed.io
Enterprise TherapeuticsJUST ADDED

Developer of drugs to treat respiratory diseases.

64
$2M · Series A Forbion Capital Partners, Epidarex Capital, Imperial Innovations 11 to 50 Health Tech, Biotech London, UK •••••••••••@enterprisetherapeutics.com
Hypervision Surgical

Precision software for eye surgery.

64
$8M · Seed Redalpine 1 to 10 Health Tech, Biotech London, UK •••••••••••@hypervisionsurgical.com
Epsilogen

Immuno-oncology company treats cancer with antibodies.

64
$2M · Series A AlbionVC, Epidarex Capital, Novartis Venture Fund 11 to 50 Health Tech, Biotech, Deep Tech, Pharma, Manufacturing, Genetics B2B London, UK •••••••••••@epsilogen.com
Multiomic Health

Precision therapeutics discovery platform.

64
$6M · Seed Hoxton Ventures 11 to 50 Biotech B2B London, UK •••••••••••@multiomic.uk
Pear Bio

Cancer treatment predictor software.

64
$14M · Series A Hoxton Ventures, Octopus Ventures, Fly Ventures 11 to 50 Health Tech, Biotech, Pharma B2B London, UK •••••••••••@pearbio.com
Flarin

Patent-protected anti-inflammatory painkiller.

64
$6M · Series A ITV AdVentures 1 to 10 Biotech, Pharma B2C London, UK •••••••••••@flarin.co.uk
Genomes

User-owned genomics database platform.

64
$20M · Series A GEM Digital 1 to 10 Health Tech, Biotech B2C London, UK •••••••••••@genomes.io
Sitryx Therapeutics

Developer of therapeutics for chronic autoimmune and inflammatory diseases.

62
$38M · Series A Sofinnova Partners, GSK, SV Health Investors 11 to 50 Health Tech, Biotech Oxford, UK •••••••••••@sitryx.com
Lifebit

Biomedical CloudOS data platform.

59
$120k · Seed Eurazeo, Connect Ventures, Techstars 51 to 100 Health Tech, Biotech, Data and Analytics, Business Intelligence B2B, SaaS London, UK •••••••••••@lifebit.ai
Sixfold Bioscience

Sixfold Bioscience develops and researches on biotechnology advances for RNA therapies.

59
$10M Y Combinator, Pi Campus 11 to 50 Health Tech, Biotech, Robotics, Manufacturing, Business Intelligence B2B London, UK •••••••••••@sixfold.bio
Better Dairy

Building the future of food, starting with dairy.

59
$2M · Seed Entrepreneur First, Vorwerk Ventures, Redalpine 1 to 10 Agritech, Foodtech, Biotech, Manufacturing B2B, B2C London, UK •••••••••••@betterdairy.co.uk
Hoxton Farms

Based in London, UK, Hoxton Farms is growing cultivated fat as an ingredient for the meat alternatives industry.

59
$3M · Seed BACKED VC, CPT Capital 11 to 50 Foodtech, Biotech, Manufacturing B2B London, UK •••••••••••@hoxtonfarms.com
Pathfinder Medical

Pathfinder is developing a novel catheter based system that provides a better way for patients to receive haemodialysis for kidney failure.

59
$11M · Series A Business Growth Fund, Parkwalk Advisors, Deepbridge Capital 1 to 10 Health Tech, Biotech, Manufacturing B2B London, UK •••••••••••@pathfindermed.com
Daye

Daye is a gynecological health company that creates products and services for vaginal treatment.

59
$5M · Seed Index Ventures, Khosla Ventures, Kindred Capital 11 to 50 Health Tech, Biotech, Manufacturing, Ecommerce, Cannabis B2C London, UK •••••••••••@yourdaye.com
ImmuONE

3D human lung model developer.

59
$2M · Seed Pioneer Group, Mercia Asset Management, Midlands Engine Investment Fund 11 to 50 Biotech, Deep Tech London, UK •••••••••••@immuone.com
Basecamp Research

Protein discovery research and manufacturing.

59
$19M · Series A SYSTEMIQ 11 to 50 Biotech, Deep Tech London, UK •••••••••••@basecamp-research.com
Nature Metrics

Developer of cutting-edge DNA techniques to monitor biodiversity.

59
$3M · Seed SYSTEMIQ, BNP Paribas, Green Angel Ventures 11 to 50 Biotech London, UK •••••••••••@naturemetrics.co.uk
Myricx Pharma

Myricx Pharma is a drug discovery company focused on developing small molecule inhibitors.

59
$6M · Seed Sofinnova Partners 1 to 10 Health Tech, Biotech, Deep Tech, Pharma B2B London, UK •••••••••••@myricxpharma.com
Opencell

OpenCell builds biotech labs in shipping containers with the aim of making biotechnology accessible and affordable.

59
$8M Seventure Partners 1 to 10 Fintech, Biotech, Proptech & Real Estate, Manufacturing B2B, SaaS London, UK •••••••••••@opencell.bio
Peptone

We are a translational biophysics company focusing on the discovery of novel therapeutics against intrinsically disordered proteins.

59
$2M Hoxton Ventures, Bessemer Venture Partners 11 to 50 Health Tech, Biotech, Pharma, Manufacturing B2B London, UK •••••••••••@peptone.io
Osler Diagnostics

Lab-quality diagnostics for anyone, anywhere, at any time.

56
$85M Oxford Science Enterprises 51 to 100 Health Tech, Biotech, Deep Tech, Pharma B2B Oxford, UK •••••••••••@oslerdiagnostics.com
MiroBio

MiroBio is Harnessing the natural control mechanisms of the immune system.

56
$97M · Series B Medicxi, Oxford Science Enterprises 1 to 10 Health Tech, Biotech, Deep Tech B2B Oxford, UK •••••••••••@mirobio.com
F2G

F2G discovers and develops novel drugs for the treatment of life-threatening fungal diseases.

56
$70M Sofinnova Partners, Novo A/S, Forbion Capital Partners 251 to 500 Health Tech, Biotech, Pharma, Genetics B2B Manchester, UK •••••••••••@f2g.com
ONI

ONI is a pioneer of super-resolution microscopy, making this advanced technology accessible to new generations of researchers.

56
$75M · Series B Axon Ventures, Oxford Science Enterprises 51 to 100 Health Tech, Biotech, Deep Tech, Robotics, Manufacturing, Developer Tools B2B Oxford, UK •••••••••••@oni.bio
ViaNautis

Drug delivery platform.

56
$24M · Series A 4BIO Capital, UCB Ventures, Business Growth Fund 1 to 10 Health Tech, Biotech Cambridge, UK •••••••••••@vianautis.com
Shorla Pharma

Oncology treatment plalform.

56
$35M · Series B Kurma Partners, Seroba Life Sciences, Enterprise Ireland 1 to 10 Biotech Cork, UK •••••••••••@shorlapharma.com
Sano Genetics

AI platform to advance precision medicine clinical trials.

56
$11M · Series A Seedcamp, Plural, MMC Ventures 11 to 50 Health Tech, Biotech B2B, SaaS Cambridge, UK •••••••••••@sanogenetics.com
Oxford Nanopore Technologies

Oxford Nanopore Technologies develops nanopore-based electronic systems for analyzing single molecules, including DNA, RNA, and proteins.

56
$275M Wellington Management 251 to 500 Health Tech, Biotech, Pharma, Robotics, Manufacturing, Genetics B2B Oxford, UK •••••••••••@nanoporetech.com
Healx

Healx is an AI-powered, patient-inspired technology company, pioneering the next generation of drug discovery for rare diseases.

56
$56M · Series B Balderton Capital, Atomico, btov Partners 51 to 100 Health Tech, AI, Biotech, Pharma, Data and Analytics, Business Intelligence B2B, SaaS Cambridge, UK •••••••••••@healx.io
Microbiotica

Microbiotica is a developer of human microbiome therapeutics intended to discover and develop live bacterial therapeutics and biomarkers.

56
$66M Seventure Partners, Cambridge Innovation Capital 11 to 50 Health Tech, Biotech, Deep Tech, Manufacturing B2B Cambridge, UK •••••••••••@microbiotica.com
Pheon Therapeutics

Pheon Therapeutics is an Antibody-Drug Conjugate (ADC) specialist that creates ADCs for a variety of difficult-to-treat cancers.

54
N/A Forbion Capital Partners 11 to 50 Health Tech, Biotech, Deep Tech, Pharma B2B London, UK •••••••••••@pheontx.com
Actimed Therapeutics

Developer of innovative treatment for muscle wasting disorders.

54
$1M · Seed Mankind Pharma 1 to 10 Biotech, Pharma London, UK •••••••••••@actimedtherapeutics.com
Sable bioJUST ADDED

AI-powered drug testing platform.

54
$1M · Pre Seed Seedcamp, Episode 1 1 to 10 AI, Biotech London, UK •••••••••••@sablebio.com
FabricNano

Cell-free chemical manufacturer to produce bio-based alternatives

54
$3M · Seed Hoxton Ventures, Atomico, BACKED VC 11 to 50 Biotech B2B London, UK •••••••••••@fabricnano.com
Epoch Biodesign

Epoch develops natural solutions to unnatural problems. First up: enzymes that transform plastics into circular chemicals.

54
$3M · Pre Seed Lowercarbon Capital, BoxGroup, Amadeus Capital 11 to 50 Biotech, Manufacturing B2B London, UK •••••••••••@epochbiodesign.com
Quaisr

Digital-twin simulator.

54
$3M · Pre Seed Crane Venture Partners 1 to 10 Biotech, Supply Chain & Logistics B2B London, UK •••••••••••@quaisr.io
BioCorteX

Computer simulation to understand drug-bacteria interactions.

54
$5M · Seed Hoxton Ventures, Sofinnova Partners 1 to 10 Biotech London, UK •••••••••••@biocortex.co.uk
Kuano

Quantum simulation platform for drug discovery.

54
$2M · Seed Ascension Ventures, ACF Investors 1 to 10 Health Tech, Biotech B2B, SaaS London, UK •••••••••••@kuano.ai
Bea Fertility

At-home fertility treatment.

54
$3M · Seed Octopus Ventures, Calm/Storm Ventures, QVentures 1 to 10 Health Tech, Biotech B2C London, UK •••••••••••@beafertility.com
Ascend Gene & Cell Therapies

Gene and cell therapy manufacturing.

53
$65M · Series A 11 to 50 Biotech London, UK •••••••••••@ascend-gctx.com
Nuclera

Nuclera makes biology accessible through desktop enzymatic protein and gene synthesis.

51
$42M · Series B Future Planet Capital, Amadeus Capital, Verve Ventures 11 to 50 Biotech, Deep Tech, Manufacturing B2B Cambridge, UK •••••••••••@nuclera.com
CellVoyantJUST ADDED

AI-powered live stem cells behaviour tracking platform.

51
$9M · Seed Air Street Capital, Octopus Ventures, Horizons Ventures 1 to 10 AI, Biotech Bristol, UK •••••••••••@cellvoyant.com
bit.bio

Bit.bio specializes in the fields of coding and biology that determine the identity of every human cell.

51
$41M · Series A Metaplanet Holdings, BlueYard Capital 101 to 250 Health Tech, Biotech, Deep Tech, Business Intelligence B2B Cambridge, UK •••••••••••@bit.bio
IsomAbJUST ADDED HIRING

Developer of antibodies to treat diabetic peripheral arterial disease.

51
$9M · Seed Broadview Ventures, MEIF Proof-of-Concept & Early Stage Fund, Mercia Asset Management 1 to 10 Health Tech, Biotech Nottingham, UK •••••••••••@isomab.bio
Mogrify

Mogrify® will transform the development of ex vivo cell therapies and pioneer a new class of in vivo reprogramming therapies.

51
$10M · Series A Astellas Venture Management, Ahren Innovation Capital, Parkwalk Advisors 101 to 250 Health Tech, Biotech, Deep Tech B2B Cambridge, UK •••••••••••@mogrify.co.uk
Mosaic Therapeutics

Anti-cancer drug developer.

51
$28M · Series A Syncona Partners LLP, Cambridge Innovation Capital 101 to 250 Biotech Cambridge, UK •••••••••••@mosaic-tx.com
Foodsteps

Foodsteps is a london-based startup that has developed a platform to help the food sector reduce its carbon footprint.

50
$4M Octopus Ventures, Ascension Ventures, Metaplanet Holdings 11 to 50 Climate Tech & Green Tech, Health Tech, Agritech, Foodtech, Biotech, Deep Tech, Energy & Nuclear, Business Intelligence B2B, SaaS London, UK •••••••••••@foodsteps.earth